Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.48 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2932360 | 0.86 | MKNK1 (0.60) | PHGDHHPGDSMN1; SMN2AKR1C3KCNH2 | |
| SCHEMBL18766579 | 0.86 | HPGD (0.45) | HPGDALDH1A1PKMATRMKNK1 | |
| SCHEMBL2926839 | 0.83 | HPGD (0.53) | PHGDHHPGDSMN1; SMN2AKR1C3KCNH2 | |
| SCHEMBL2931412 | 0.80 | CHEK1 (0.62) | HPGDSMN1; SMN2ALDH1A1ATRMKNK1 | |
| SCHEMBL21058591 | 0.80 | PHGDH (0.57) | PHGDHHPGDSMN1; SMN2AKR1C3ALDH1A1 | |
| SCHEMBL2933173 | 0.79 | HPGD (0.50) | PHGDHHPGDSMN1; SMN2KCNH2ALDH1A1 | |
| SCHEMBL18766581 | 0.79 | MEN1 (0.59) | ATRHDAC4 | |
| SCHEMBL3993564 | 0.79 | PHGDH (0.63) | PHGDHHPGDSMN1; SMN2AKR1C3PKM | |
| SCHEMBL2936901 | 0.78 | FASN (0.53) | HPGDSMN1; SMN2JAK2RIPK1 | |
| SCHEMBL2927882 | 0.78 | RIPK1 (0.55) | HPGDSMN1; SMN2ATRMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (publ) (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | PHGDH 3961/4885HPGD 3066/4885SMN1; SMN2 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.